[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
January 1986

Percutaneous Absorption of Minoxidil-Reply

Author Affiliations

Dermatopharmacology Laboratory University of Washington School of Medicine Seattle, WA 98195

Arch Dermatol. 1986;122(1):15-16. doi:10.1001/archderm.1986.01660130017008

In Reply.—  The letter by el-Azhary and Goldberg raises issues regarding the metabolic fate of minoxidil following topical application. Could metabolism and/or binding of minoxidil or its metabolites in the skin have affected the results of my study and led to erroneous conclusions regarding the values determined for total minoxidil absorption?The technique I used is that most commonly used for the study of percutaneously administered drugs, as popularized by Feldmann and Maibach.1,2 In essence, the method uses the measurement of total urinary excretion of radioactivity following topical application as a means to calculate total percutaneous absorption. No distinction is made between the excretion of the parent drug or the metabolite, since the appearance of either in the urine can only occur as a consequence of percutaneous absorption. Whether the parent drug is metabolized within the skin systemically or remains unmetabolized is unimportant to the calculation of total absorption.

First Page Preview View Large
First page PDF preview
First page PDF preview